Phase I Study of NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma, for Whom Treatment With Ipilimumab is Indicated

Trial Profile

Phase I Study of NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma, for Whom Treatment With Ipilimumab is Indicated

Discontinued
Phase of Trial: Phase I

Latest Information Update: 05 Jun 2018

At a glance

  • Drugs Cancer vaccine NY-ESO-1 (Primary) ; Ipilimumab (Primary) ; Montanide ISA-51 (Primary) ; Poly ICLC (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 05 Jun 2018 Results (n=8) presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
    • 10 Jun 2017 Biomarkers information updated
    • 16 Jun 2016 Planned End Date changed from 1 May 2016 to 1 Dec 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top